AQP4 and neuromyelitis optica: In 2004, the discovery of positive antiaquaporin-4 antibodies (AQP4-IgG) in serum of the majority of NMO patients led to significant progress in the clinical characterization of the disease, now acknowledged as a distinct entity with different immunological, clinical and epidemiological features3,4.